Trend of clinical outcome and surrogate markers during titration of β-blocker in heart failure patients with reduced ejection fraction - Relevance of achieved heart rate and β-blocker dose -

Circulation Journal

Volumn 77, Issue 4, 2013, Pages 1001-1008

  Kato, Naoko ^a   Kinugawa, Koichiro ^a   Imamura, Teruhiko ^a   Muraoka, Hironori ^a   Minatsuki, Shun ^a   Inaba, Toshiro ^a   Maki, Hisataka ^a   Shiga, Taro ^a   Hatano, Masaru ^a   Yao, Atsushi ^a   Komuro, Issei ^a   Nagai, Ryozo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Beta blocker; Heart failure; Heart rate; Morbidity; Mortality

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; CANDESARTAN; CARVEDILOL; ENALAPRIL; IMIDAPRIL; LOSARTAN; VALSARTAN;

ADULT; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; COMORBIDITY; DISEASE MARKER; DRUG DOSE TITRATION; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; RESTING HEART RATE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; AGED; BIOLOGICAL MARKERS; CARBAZOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART FAILURE; HEART RATE; HUMANS; MALE; MIDDLE AGED; PROPANOLAMINES; STROKE VOLUME;

EID: 84875517744     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-1241     Document Type: Article

References (30)

1. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251-259.
2. Heidenreich PA, Sahay A, Kapoor JR, Pham MX, Massie B. Divergent trends in survival and readmission following a hospitalization for heart failure in the Veterans Affairs health care system 2002 to 2006. J Am Coll Cardiol 2010; 56: 362-368.
3. Kato N, Kinugawa K, Seki S, Shiga T, Hatano M, Yao A, et al. Quality of life as an independent predictor for cardiac events and death in patients with heart failure. Circ J 2011; 75: 1661-1669.
4. Kinugawa K. How to treat stage D heart failure? When to implant left ventricular assist devices in the era of continuous flow pumps? Circ J 2011; 75: 2038-2045.
5. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: e391-e479.
6. The Japanese Circulation Society. Guidelines for treatment of chronic heart failure (JCS 2010). http://www.j-circ.or.jp/guideline/pdf/ JCS2010_matsuzaki_h.pdf (accessed October 1, 2012).
7. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology: Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787-1847.
8. Maggioni AP, Dahlstrom U, Filippatos G, Chioncel O, Leiro MC, Drozdz J, et al. EURObservational Research Programme: The Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 2010; 12: 1076-1084.
9. Gheorghiade M, Albert NM, Curtis AB, Thomas Heywood J, McBride ML, Inge PJ, et al. Medication dosing in outpatients with heart failure after implementation of a practice-based performance improvement intervention: Findings from IMPROVE HF. Congest Heart Fail 2012; 18: 9-17.
10. Gattis WA, O'Connor CM, Gallup DS, Hasselblad V, Gheorghiade M, IMPACT-HF Investigators and Coordinators. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: Results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. J Am Coll Cardiol 2004; 43: 1534-1541.
11. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al. Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure). Am J Cardiol 2008; 102: 1524-1529.
12. Fowler MB, Lottes SR, Nelson JJ, Lukas MA, Gilbert EM, Greenberg B, et al. Beta-blocker dosing in community-based treatment of heart failure. Am Heart J 2007; 153: 1029-1036.
13. Böhm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, et al. Heart rate as a risk factor in chronic heart failure (SHIFT): The association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010; 376: 886-894.
14. Flannery G, Gehrig-Mills R, Billah B, Krum H. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol 2008; 101: 865-869.
15. McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW. Meta-analysis: Beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009; 150: 784-794.
16. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349-1355.
17. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999; 353: 9-13.
18. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-2007.
19. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure: MOCHA Investigators. Circulation 1996; 94: 2807-2816.
20. Simon T, Mary-Krause M, Funck-Brentano C, Lechat P, Jaillon P. Bisoprolol dose-response relationship in patients with congestive heart failure: A subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS II). Eur Heart J 2003; 24: 552-559.
21. Wikstrand J, Hjalmarson A, Waagstein F, Fagerberg B, Goldstein S, Kjekshus J, et al. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: Analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol 2002; 40: 491-498.
22. Hori M, Sasayama S, Kitabatake A, Toyo-oka T, Handa S, Yokoyama M, et al. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: The Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 2004; 147: 324-330.
23. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992.
24. Cullington D, Goode KM, Clark AL, Cleland JGF. Heart rate achieved or beta-blocker dose in patients with chronic heart failure: Which is the better target? Eur J Heart Fail 2012; 14: 737-747.
25. Metra M, Torp-Pedersen C, Swedberg K, Cleland JGF, Di Lenarda A, Komajda M, et al. Influence of heart rate, blood pressure, and betablocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: Results from the COMET trial. Eur Heart J 2005; 26: 2259-2268.
26. Mulder P, Barbier S, Chagraoui A, Richard V, Henry JP, Lallemand F, et al. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 2004; 109: 1674-1679.
27. Tardif JC, O'Meara E, Komajda M, Bohm M, Borer JS, Ford I, et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: Results from the SHIFT echocardiography substudy. Eur Heart J 2011; 32: 2507-2515.
28. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study. Lancet 2010; 376: 875-885.
29. Nishiyama K, Tsutamoto T, Yamaji M, Kawahara C, Yamamoto T, Fujii M, et al. Dose-dependent prognostic effect of carvedilol in patients with chronic heart failure: Special reference to transcardiac gradient of norepinephrine. Circ J 2009; 73: 2270-2275.
30. Castagno D, Skali H, Takeuchi M, Swedberg K, Yusuf S, Granger CB, et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: Results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. J Am Coll Cardiol 2012; 59: 1785-1795.